• Clinical Data
  • Subgroup Analyses
  • Efficacy In 2L Population

TRODELVY 200mg

Clinical Data

Consistent outcomes in post hoc subgroup analyses

TRODELVY helped patients in the 2L population experience improved outcomes vs single-agent chemotherapy*1

OS in 2L population
OS in 2L population
1 OUT OF 7 PATIENTS (14%) were treated with only 1 prior regimen in the metastatic setting

In the ASCENT trial, 1 OUT OF 7 PATIENTS (14%) were treated with only 1 prior regimen in the metastatic setting2

Adapted from Carey A, et al. 2021.

*Assessed by independent central review in the brain metastases negative population. This ASCENT subanalysis of patients with mTNBC who recurred ≤12 months after (neo) adjuvant chemotherapy and then only received 1 line of therapy in the metastatic setting assessed the benefit of TRODELVY in this subgroup vs the overall trial population

ABBREVIATIONS:

2L, second line; CBR, clinical benefit rate; CI, confidence interval; CR, complete response; DOR, duration of response; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response.

REFERENCES:

  1. Carey L.A. et al., Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis, NPJ Breast Cancer 2022 Jun 9;8(1):72. doi: 10.1038/s41523-022-00439-5.
  2. TRODELVY (sacituzumab govitecan) Summary of Product Characteristics, July 2023.